Can J Clin Pharmacol 2009; 16: e400–6PubMed 12. Donato JL, Koizumi F, Pereira AS, et al. Simultaneous determination of dextromethorphan, dextrorphan and doxylamine in human plasma by HPLC coupled to electrospray ionization tandem mass spectrometry: application to a pharmacokinetic
study. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 899: 46–56PubMedCrossRef”
“Introduction Levofloxacin 0.5% ophthalmic solution (Cravit® ophthalmic solution 0.5%; Santen Pharmaceutical Co., Ltd., Osaka, Japan) is an antiSotrastaurin bacterial eye drop formulation, which Poziotinib cell line contains the active ingredient levofloxacin, a synthetic antimicrobial agent of the fluoroquinolone family.[1] Fluoroquinolones are known to exert antimicrobial activity through inhibition of DNA gyrase, an enzyme involved in bacterial DNA synthesis. They have been used extensively for the treatment of bacterial selleckchem infections in clinical practice because of their potent activity against a wide range of Gram-positive and Gram-negative microbes. Furthermore, topical fluoroquinolones, such as ophthalmic solutions containing norfloxacin or ofloxacin, have been widely prescribed
for the treatment of external ocular bacterial infections.[2] Levofloxacin, an L-isomer of ofloxacin, has two times greater antimicrobial activity than ofloxacin[3] and has high water solubility at a neutral pH, allowing for the preparation of high-concentration formulations. Clinical trials of levofloxacin 0.5% ophthalmic solution revealed that levofloxacin ophthalmic solution was superior to ofloxacin ophthalmic solution.[4–7] As a result, levofloxacin 0.5% ophthalmic solution was approved and marketed in Japan in 2000 for the treatment of bacterial conjunctivitis or other external ocular infections Osimertinib manufacturer and for perioperative use during ocular surgery.[1] It is approved for the treatment of bacterial conjunctivitis in the US (Quixin®)[8] and is also approved in several European countries for the treatment
of ocular infections (Oftaquix®).[9] Japanese regulatory authority policy required monitoring of the safety and efficacy of levofloxacin 0.5% ophthalmic solution for the treatment of ocular bacterial infections for up to 6 years after its approval. In accordance with this, surveillance was conducted on the use of levofloxacin 0.5% ophthalmic solution, initiated immediately after levofloxacin was launched on the market. In this article, we present the results of this post-marketing surveillance of levofloxacin 0.5% ophthalmic solution used in everyday clinical practice in a large patient population. Methods Patients This survey was designed to investigate the safety and efficacy of levofloxacin 0.5% ophthalmic solution in patients who received treatment for external ocular bacterial infections in regular clinical practice.